• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Guard Therapeutics

1.60 SEK

+3.77 %

Less than 1K followers

GUARD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.77 %
+30.56 %
+3.77 %
+8.71 %
+9.08 %
-91.00 %
-72.23 %
-97.73 %
-99.91 %

Guard Therapeutics is engaged in the development of drugs in the field of oxidative stress. The company focuses primarily on research, development and commercialization of drugs that aim to prevent the onset and complications of acute kidney injury. The drug has been shown in preclinical studies to protect exposed tissue and support regenerative processes. The company is headquartered in Lund.

Read more
Market cap
32.23M SEK
Turnover
296.44K SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Financial calendar
20.7.
2026

Extraordinary general meeting '26

20.8.
2026

Interim report Q2'26

12.11.
2026

Interim report Q3'26

Press release6 hours ago

Guard Therapeutics Initiates Transaction Process for the GTX Platform

Guard Therapeutics
Regulatory press releaseyesterday

Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma

Guard Therapeutics
Regulatory press release4/9/2026, 3:10 PM

Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market

Guard Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release3/31/2026, 1:45 PM

Guard Therapeutics provides update on strategic review

Guard Therapeutics
Regulatory press release2/5/2026, 3:45 PM

Guard Therapeutics Announces Changes to the Company’s Management Team

Guard Therapeutics
Press release2/5/2026, 3:35 PM

Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review

Guard Therapeutics
Press release1/15/2026, 3:55 PM

Guard Therapeutics Partners in EU Consortium For Alport Syndrome

Guard Therapeutics
Press release12/30/2025, 1:20 PM

DNB Carnegie Access: Guard Therapeutics: Discontinuing coverage

Guard Therapeutics
Regulatory press release12/16/2025, 1:20 PM

Guard Therapeutics presents the Nomination Committee for 2026

Guard Therapeutics
Press release12/8/2025, 3:00 PM

Guard Therapeutics appoints Redeye as financial advisor in the strategic review

Guard Therapeutics
Regulatory press release12/5/2025, 1:40 PM

Guard Therapeutics changes Certified Adviser to Redeye AB

Guard Therapeutics
Press release12/5/2025, 5:21 AM

DNB Carnegie Access: Guard Therapeutics: Challenging path forward

Guard Therapeutics
Regulatory press release12/4/2025, 6:50 PM

Guard Therapeutics Explores Strategic Alternatives

Guard Therapeutics
Press release12/4/2025, 6:45 PM

Guard Therapeutics Provides Assessment of Full POINTER Study Results

Guard Therapeutics
Press release11/13/2025, 4:17 PM

DNB Carnegie Access: Guard Therapeutics: Awaiting further company communication – Q3 review

Guard Therapeutics
Press release10/27/2025, 8:33 AM

DNB Carnegie Access: Guard Therapeutics: POINTER data – endpoints not met

Guard Therapeutics
Regulatory press release10/26/2025, 10:45 AM

Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study

Guard Therapeutics
Press release10/17/2025, 6:00 AM

Guard Therapeutics to Present Late-Breaking Phase 2b POINTER Results at ASN Kidney Week 2025

Guard Therapeutics
Regulatory press release10/5/2025, 12:15 PM

Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study

Guard Therapeutics
Press release9/30/2025, 10:22 AM

DNB Carnegie Access: Guard Therapeutics: POINTER data preview: high risk, high potential reward - corrected version

Guard Therapeutics